N-Methylnorsalsolinol (NMNSAL), also known as 2-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (2-MDTIQ), is an endogenous dopaminergic neurotoxin, present in healthy individuals and at high levels in the cerebrospinal fluid of individuals with Parkinson's disease. Structurally, it is an isoquinolinol, which is norsalsolinol substituted with a methyl group at position 2. It can also be characterized as a rigid cyclized analogue of epinine. The biosynthesis of the neurotoxin N-methynorsalsolinol is carried out by enzymatic condensation of dopamine into salsolinol with its subsequent methylation under the action of neutral N-methyltransferase. In rats and humans, the biosynthesis of the neurotoxin N-methylnorsalsolinol is carried out by Pictet-Spengler condensation from N-methyldopamine (epinine) and aldehydes. N-Methylnorsalsolinol has been detected as a metabolite in humans and rodents, as it is formed in the process of side metabolism of dopamine.
Pharmacology
Pharmacodynamics N-Methylnorsalsolinol has shown high biological activity. It inhibits the tyrosine hydroxylase enzyme in vitro. It also inhibits the activity of the enzyme monoamine oxidase (In particular MAO-A), disrupting the natural breakdown of dopamine in the basal ganglia. It probably also blocks the mechanisms of transport and uptake of neurotransmitters on the membranes of nerve cells.
See also Substituted tetrahydroisoquinoline
References



